By Measuring The Effect On A Living Organism, Tissue, Or Cell Patents (Class 506/10)
  • Patent number: 10784093
    Abstract: A system and method for processing long scan data from a mass spectrometer is described. The long scan data is broken into multiple discrete subsets and each of the multiple subsets are padded by adding additional strings of data on either end of the subset. Each of the multiple subsets is deconvolved and overhang errors are corrected for on each deconvolved subset. A deconvolved full data set is then assembled from the deconvolved subsets.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: September 22, 2020
    Assignee: THERMO FINNIGAN LLC
    Inventor: Ping F. Yip
  • Patent number: 10745739
    Abstract: Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells. The mineral coatings bind polynucleotides and provide a source of calcium and phosphate ions to enhance transfection. The present disclosure also provides a high throughput platform for screening non-viral transfection of cells. The methods of the present disclosure also provide an advantageous polynucleotide delivery platform because the mineral coatings may be deposited on various medical device materials after being specifically developed using the high throughput screening platform.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 18, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William L. Murphy, Siyoung Choi, Xiaohua Yu
  • Patent number: 10704099
    Abstract: The present invention relates to a method for determining a decrease in the functions of the hippocampus by using the correlation between a micro RNA (miRNA) and an N-methyl-D-aspartate receptor (NMDAR), a method for inhibiting the decrease in the functions, and a method for screening for inhibitors of the decrease in the functions.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 7, 2020
    Assignees: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY, INSTITUTE FOR BASIC SCIENCE
    Inventors: Keetae Kim, Hong Gil Nam, Chand Parvez Danka Mohammed
  • Patent number: 10669562
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 2, 2020
    Assignee: SELEXIS S.A.
    Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Patent number: 10655102
    Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: May 19, 2020
    Assignee: Emmetrope Ophthalmics LLC
    Inventors: Jeffrey L. Goldberg, Noelia J. Kunzevitzky
  • Patent number: 10648968
    Abstract: A method for evaluating in vitro the effect of a xenobiotic (e.g., a drug) on drug metabolism in hepatocytes. The kit comprises a first culture of hepatocytes, a portion of in vitro xenobiotic-stimulated biological sample, and instructions for incubating the first culture of hepatocytes with the portion of in vitro xenobiotic-stimulated biological sample, and analyzing the activity, expression, or a combination thereof of a biomarker in the hepatocytes to evaluate the effect of the xenobiotic on drug metabolism in the hepatocytes.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: May 12, 2020
    Assignee: XenoTech, L.L.C.
    Inventors: Maciej Czerwinski, David Benjamin Buckley, Faraz Kazmi
  • Patent number: 10640537
    Abstract: The present invention provides for a system comprising (a) a first nucleic acid comprising a nucleotide sequence encoding a nucleotide sequence of interest operatively linked to a promoter comprising a repressor polypeptide binding site, and (b) a second nucleic acid comprising a nucleotide sequence encoding a repressor polypeptide having at least 70% amino acid identity with EilR, SmvR, KmrR, RcdA, or QacR; wherein expression of the nucleotide sequence of interest from the promoter is induced by the presence of a hydrophobic inducer, such as a hydrophobic cation inducer, such as a triarylmethane, acridine, phenazine, phenothiazine, or xanthene.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 5, 2020
    Assignee: The Regents of the University of California
    Inventor: Thomas L. Ruegg
  • Patent number: 10632169
    Abstract: Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement. In a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 28, 2020
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, William R. Swindell
  • Patent number: 10626445
    Abstract: The present invention generally relates to a set of early developmental reference data or “lineage scorecard” for stem cells, and methods, systems and kits to generate a lineage scorecard for predicting the functionality and suitability of stem cell lines. In some aspects, methods for generating a scorecard comprises measuring the gene expression of a plurality of early developmental genes, such as pluripotent, early ectoderm, early mesoderm and early endoderm genes to predict the pluripotency and differentiation potential of the stem cell line and its functionality and/or suitability for a desired use. In some embodiments, a reference scorecard can be compared with the test stem cell line scorecard to accurately predict the utility and/or identify specific characteristics of the stem cell line, e.g., to determine its suitability for downstream applications, e.g., therapeutic use, drug screening, toxicity assays, differentiation into a desired cell lineage, etc.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 21, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Alexander Meissner, Alexander Tsankov, Veronika Akopian
  • Patent number: 10591486
    Abstract: A method for detecting an interaction between one or more protein bait and one or more candidate prey in a eukaryotic cell, comprising the steps of: a) providing an eukaryotic cell expressing (i) one or more protein bait, and (ii) one or more candidate prey, wherein said protein bait comprises a bait moiety and a polymerized-tubulin binding moiety. b) determining the occurence of an interaction between said one or more protein bait and said one or more candidate prey in the eukaryotic cell, wherein said protein bait is bound to polymerized tubulin in the eukaryotic cell, thereby localizing said one or more candidate prey along said polymerized tubulin, thereby detecting said interaction.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: March 17, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE D'EVRY — VAL D-ESSONNE
    Inventors: David Pastre, Michel Cailleret, Patrick Curmi, Mirela Boca
  • Patent number: 10591458
    Abstract: Embodiments described herein are directed to devices for supporting growth of anisotropic muscle tissue layers and in vitro readout and quantification of force generated by the tissue layers using one or more strain-sensing elements integrated into the device. Embodiments also include multiplexed apparatuses of multiple independent devices, methods of fabricating the devices and apparatuses, and methods of using the devices and apparatuses.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 17, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin Kit Parker, Johan Ulrik Lind, Jennifer Ann Lewis, Joost Johan Vlassak, Hongyan Yuan, Travis Alexander Busbee, Ian Perkins, Christophe Chantre
  • Patent number: 10584369
    Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Senex Biotechnology, Inc.
    Inventors: Igor B Roninson, Donald C Porter, Serena Altilia
  • Patent number: 10570437
    Abstract: A library of cell strains is characterized by culturing cells at spatially defined and separated positions in a culturing device (1) and determining a phenotypic characteristic of each cell strain in the culturing device (1). The cells are fixated at the spatially defined and separated positions in the culturing device (1) followed by in situgenotyping a respective variable region (150) of each cell strain at the spatially defined and separated positions in the culturing device (1). Each respective phenotypic characteristic is connected to each respective genotype based on the spatially defined and separated positions in the culturing device (1).
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: February 25, 2020
    Assignee: ASTREGO DIAGNOSTICS AB
    Inventors: Johan Elf, Ove Öhman, George Church
  • Patent number: 10488362
    Abstract: Example paper substrate diagnostic apparatus and related methods and systems are disclosed herein. An example apparatus includes a hydrophobic substrate having a first end and a second end opposite the first end. The apparatus includes a detection zone on a first surface of the substrate, the detection zone defining an area to sense an analyte in a sample, the detection zone comprising a first electrode and a second electrode disposed on the first surface of the substrate and a layer of hydrophilic ink disposed on the two electrodes and an area between the first and second electrodes. The apparatus also includes a channel comprising hydrophilic ink disposed on the first surface of the substrate, the channel having an inlet section adjacent the first end of the substrate, a middle section, and an outlet section in contact with the layer of hydrophilic ink. The channel is to transfer a fluid sample from the inlet section to the layer of hydrophilic ink.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: November 26, 2019
    Assignee: ABBOTT LABORATORIES
    Inventor: Sophie Laurenson
  • Patent number: 10450566
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 22, 2019
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Patent number: 10436771
    Abstract: Systems and methods for targeted therapy based on single-cell stimulus perturbation response. In one embodiment, a method for optimizing stimulus combinations for therapy includes receiving a cell sample, treating the cell sample with a plurality of stimuli by treating a different portion of the cell sample with one of the plurality of stimuli for each of the plurality of stimuli, labeling the cell sample with a plurality of metal-conjugated probes, analyzing the cell sample using a mass spectrometer, obtaining mass spectrometry data from the mass spectrometer, identifying subpopulations within the cell sample using the mass spectrometry data, computing stimulus effects, generating a nested-effects model using the mass spectrometry data, and scoring stimuli combinations using the computing device, wherein the stimulus combinations are combinations made from the plurality of stimuli.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 8, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Benedict Anchang, Sylvia K. Plevritis
  • Patent number: 10392649
    Abstract: A polypeptide biosensor that detects free NAD+ is disclosed. The polypeptide comprises a first fragment from an NAD+ dependent DNA ligase acetylation domain, a second fragment from the NAD+ dependent DNA ligase acetylation domain, and a fluorescent protein, wherein the fluorescent protein is positioned between the two DNA ligase acetylation domain fragments. Also disclosed are expression vectors comprising the biosensor as well as methods of using the biosensor to detect NAD+.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 27, 2019
    Assignee: Oregon Health & Science University
    Inventors: Richard Goodman, Michael Cohen, Lulu Cambronne, Melissa Stewart
  • Patent number: 10384207
    Abstract: Apparatus and methods for determining whether a test compound induces cell activity, changes cell activity, prevents cell activity, or inhibits cell activity. An embodiment comprises placing a test compound solution in contact with a cell suspension media containing cells, diffusing the test compound solution into the cell suspension from one or more sides, and detecting activity in the cells with respect to their distance from the side from which the test compound is diffusing. Embodiments may provide an apparatus that allows a side source, a point source, or both, from which a test compound solution diffuses into a cell suspension media and contacts cells. Detecting cell activity may involve detecting activity in a first cell group proximate to the side from which the test compound is diffusing, and detecting activity in a second cell group farther than the first cell group from the side from which the test compound is diffusing.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: August 20, 2019
    Assignee: Neuro Probe Incorporated
    Inventor: Richard H. Goodwin, Jr.
  • Patent number: 10316293
    Abstract: The present invention relates to the field of pluripotent stem cell culture and methods facilitate pluripotent stem cell culture at industrial levels.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: June 11, 2019
    Assignee: Janssen Biotech, Inc.
    Inventor: Shelley Nelson
  • Patent number: 10246680
    Abstract: The present invention provides compositions and methods for the culture and maintenance of pluripotent stem cells. More particularly, the present invention provides for compositions and methods for culturing, maintaining, growing and stabilizing primate pluripotent stem cells in a feeder-free defined media further comprising human serum, or a soluble attachment component of the human serum, for promoting cell attachment.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 2, 2019
    Assignee: VIACYTE, INC.
    Inventors: Allan J Robins, Thomas C Schulz
  • Patent number: 10227587
    Abstract: The disclosure relates to a method for constructing a plasma Deoxyribonucleic acid (DNA) sequencing library. The method includes: extracting a plasma DNA; making the plasma DNA ligate to a sequencing linker, and purifying a ligation product; performing Polymerase Chain Reaction (PCR) amplification for the purified ligation product, purifying the PCR amplification product, and obtaining the plasma DNA sequencing library, wherein, the method does not include the step of performing 5?-terminus phosphorylation for the plasma DNA.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: March 12, 2019
    Assignee: Berry Genomics Co., Ltd.
    Inventors: Jianguang Zhang, Yang Gao, Yanbin Shi, Di Chen, Feng Tian
  • Patent number: 10053692
    Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: August 21, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Nicola Aceto, Daniel Arie Haber, Shyamala Maheswaran
  • Patent number: 10000807
    Abstract: The disclosure describes the effects of transcription mediated from a promoter on the transcription mediated by divergently coupled supercoiling-sensitive promoter. Transcription initiated from a promoter inhibits transcription mediated by a specific supercoiling-sensitive promoter that is divergently coupled to the promoter. A gyrase inhibitor relieves this inhibition and substantially increases the transcription mediated by the specific supercoiling-sensitive promoter that is divergently coupled to another promoter. Accordingly, the invention pertains to a method for identifying a compound as a gyrase inhibitor or not a gyrase inhibitor based on differential expression of genes under the control of divergently coupled promoters in the presence of the compound. Another embodiment of the invention provides an assay for identifying one or more compounds from a library of compounds as a gyrase inhibitor.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 19, 2018
    Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Fenfei Leng, Xiaoduo Zhi, Samantha Dages, Kelley Dages
  • Patent number: 9983195
    Abstract: Described are three-dimensional, engineered, biological breast tissues, adipose tissues, and tumor models, including breast cancer models.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: May 29, 2018
    Assignee: Organovo, Inc.
    Inventors: Shelby Marie King, Deborah Lynn Greene Nguyen, Vivian A. Gorgen, Benjamin R. Shepherd, Sharon C. Presnell
  • Patent number: 9957506
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 1, 2018
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Patent number: 9850483
    Abstract: Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael F. Clarke, Stephen R. Quake, Piero D. Dalerba, Huiping Liu, Anne A. Leyrat, Tomer Kalisky, Maximilian Diehn, Michael Rothenberg, Jianbin Wang, Neethan Lobo
  • Patent number: 9822184
    Abstract: Certain embodiments are directed to composition and methods related to DCLK1-S specific binding agents.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 21, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Pomila Singh, Shubhashish Sarkar, Malaney O'Connell
  • Patent number: 9816928
    Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring heme and oxygen. Biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest. Model cells expressing the biosensors can be contacted with putative bioactive agents to determine possible activities.
    Type: Grant
    Filed: November 26, 2016
    Date of Patent: November 14, 2017
    Assignee: Tempo Bioscience Inc.
    Inventor: Angela Huang
  • Patent number: 9803167
    Abstract: The present disclosure relates to stretching apparatus and method for aligning microfibrils. Specifically, the present disclosure provides an apparatus for aligning microfibrils along a single direction, which includes: a first elastic substrate onto which a composition containing microfibrils is loaded; and a stretching module which stretches the width of the elastic substrate. In accordance with the apparatus the present disclosure, microfibrils or cells may be aligned along a particular direction simply by pulling and then releasing the elastic substrate. The present disclosure is also useful for culturing of the aligned cells because the physiological activity of the cells can be maintained and cytotoxicity can be prevented.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 31, 2017
    Assignee: Korea Institute of Science and Technology
    Inventors: Nakwon Choi, Eun-Mi Hur, Sohyun Kim, Sun-Kyoung Im, Eui Sung Yoon, Changjoon Justin Lee
  • Patent number: 9657360
    Abstract: The present invention relates to methods of detecting an increased likelihood of virus infection in a subject. In particular, the present invention relates to methods of detecting an increased likelihood of virus infection in a subject by detecting an altered level of at least one microRNA (miRNA), as well as methods of treating or preventing virus infection. The present invention also relates to nucleotide arrays, oligonucleotides and kits useful for the detection of miRNAs associated with an increased likelihood of virus infection in a subject.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 23, 2017
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Cameron Stewart, Andrew Bean
  • Patent number: 9518979
    Abstract: A novel assay using plated (cultured) human hepatocytes is disclosed. In this assay, cryopreserved human hepatocytes are thawed and cultured for 4 hours to allow attachment, followed by incubation with compounds for 24 hours. After the 24 hour incubation, aliquots can be collected for quantification of the remaining parent compounds. The remaining incubated media are transferred to freshly thawed and cultured cryopreserved hepatocyte and incubated for another 24 hour period. The process can be repeated daily resulting in accumulated incubation durations of multiple days. The innovation is the use of a new culture on each day, thereby overcoming the known decrease in metabolic activity of hepatocytes with time in culture.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: December 13, 2016
    Inventor: Albert P Li
  • Patent number: 9365640
    Abstract: Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: June 14, 2016
    Assignee: CELGENE CORPORATION
    Inventors: Antonia Lopez-Girona, Peter H. Schafer, Anita Gandhi, Derek Mendy, Thomas O. Daniel
  • Patent number: 9255124
    Abstract: The disclosed invention relates to methods of modifying peptide compositions to increase stability and delivery efficiency. Specifically, the disclosed invention relates to methods to increase the stability and delivery efficiency of protein kinase C (PKC) modulatory peptide compositions. A “therapeutic peptide composition” comprises a “carrier peptide” and a “cargo peptide.” A “carrier peptide” is a peptide or amino acid sequence within a peptide that facilitates the cellular uptake of the therapeutic peptide composition. The “cargo peptide” is a PKC modulatory peptide. Peptide modifications to either the carrier peptide, the cargo peptide, or both, which are described herein increase the stability and delivery efficiency of therapeutic peptide compositions by reducing disulfide bond exchange, physical stability, reducing proteolytic degradation, and increasing efficiency of cellular uptake.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: February 9, 2016
    Assignee: KAI PHARMACEUTICALS, INC.
    Inventor: Derek Maclean
  • Patent number: 9186673
    Abstract: Multi-well plates having contoured well designs allow multi-stage high throughput parallel assaying of ion channels or ion transporters. A well of a multi-well plate has a bottom region that is sized and shaped to simultaneously accommodate a sensing electrode and a pipette for delivering test compounds, wash fluid, and optionally ligands. The multi-well plates when coupled with an instrument having a pipette head and an electrode plate facilitates fluidic contact between cells and fluids delivered via a pipette for washing of wells with buffers or other wash solutions for serial exposure of test cells to various reagents or other stimuli. The control and test experiments are performed on the same cell (or cells) in a single well.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 17, 2015
    Assignee: Molecular Devices, LLC
    Inventor: Edward D. Verdonk
  • Patent number: 9183350
    Abstract: Apparatus, methods, and other embodiments associated with objectively predicting biochemical recurrence (BCR) with cell orientation entropy (COrE) are described. One example apparatus includes a set of logics that associate directional disorder with a risk of biochemical recurrence in a tissue. A first logic detects a cell in the tissue, segments boundaries of the cell, and calculates a cell direction for the cell. A second logic constructs a localized sparsified subgraph whose nodes represent centroids of the cells, defines pairwise spatial relationships between the cells, and constructs a directional co-occurrence matrix based on the spatial relationships. A third logic derives second order statistical features from the co-occurrence matrix, and produces a BCR risk score as a function of the second order statistical features. The second order statistical features include the entropy of the directional organization of the cells.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: November 10, 2015
    Inventors: Anant Madabhushi, George Lee, Sahirzeeshan Ali, Rachel Sparks
  • Patent number: 9163263
    Abstract: The invention provides for compositions and methods for producing isoprene using isoprene synthase variants with improved properties.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 20, 2015
    Assignees: The Goodyear Tire & Rubber Company, Danisco US Inc.
    Inventors: Zachary Q. Beck, David A. Estell, Jeffrey V. Miller, James Ngai, Christopher L. Rife, Derek H. Wells
  • Patent number: 9150850
    Abstract: The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds).
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: October 6, 2015
    Assignees: CORNELL RESEARCH FOUNDATION, INC., RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Matthew DeLisa, George Georgiou, Dujduan Waraho
  • Patent number: 9153024
    Abstract: A method and system for predicting spatial and temporal distributions of therapeutic substance carriers within a body of a user, comprising: at a computing system, receiving an image dataset and a spectra dataset of a therapeutic substance carrier generated from at least one of an imaging model and a spectra-generating module; transforming the image dataset and the spectra dataset into a set of characteristics, wherein the set of characteristics comprises electrotopological characteristics and geometrical characteristics; generating a set of pharmacokinetic parameters and a set of pharmacodynamic parameters for the therapeutic substance carrier based upon the set of characteristics and a transformation model; and transforming the set of pharmacokinetic parameters and the set of pharmacodynamic parameters into a spatial distribution and a temporal profile of the therapeutic substance carrier, based upon a predictive model incorporating physiological parameters of the body, thereby predicting distributions of t
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: October 6, 2015
    Assignee: CRIXlabs, Inc.
    Inventor: Shalini Ananda Yogendran
  • Publication number: 20150148256
    Abstract: A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 28, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN GILBERT POMPER, YIMAO ZHANG, JOHN LATERRA
  • Publication number: 20150140075
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150141284
    Abstract: The invention relates to the field of medicine. The invention provides methods for generating glatiramer-acetate-specific human T-cell lines, and assays that use these T-cell lines for demonstrating immunological identity between glatiramer acetate preparations. These assays allow sensitive and accurate comparison of glatiramer acetate preparations, and find utility as lot-release assays.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Jeffrey P. Smith, Peter E. Lipsky, Anne Lodge
  • Publication number: 20150143557
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: September 22, 2014
    Publication date: May 21, 2015
    Inventors: KENYA HONDA, KOJI ATARASHI, KIKUJI ITOH, TAKESHI TANOUE
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20150140015
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 21, 2015
    Inventor: Thierry VOISON
  • Publication number: 20150143577
    Abstract: The present invention provides methods and compositions for the identification and selection of loci modulating phenotypic expression of an herbicide tolerance trait in plant breeding. In addition, methods are provided for screening germplasm entries for the performance and expression of this trait.
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Applicant: Monsanto Tecnology LLC
    Inventors: Mindy L. DeVries Gelder, Paul Feng, Jesse J. Gilsinger, Floyd G. Hancock, Ivan Husic, James Narvel, Curtis W. Scherder, Dean A. Ulbrich
  • Publication number: 20150141289
    Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
  • Publication number: 20150140077
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150133524
    Abstract: The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent cell death related to ischemia.
    Type: Application
    Filed: October 15, 2014
    Publication date: May 14, 2015
    Inventors: Chi V. Dang, Jung-whan Kim, Gregg L. Semenza
  • Publication number: 20150133341
    Abstract: The present invention is concerned with an in vitro method of diagnosing cancer in a tissue sample, wherein said tissue sample is obtained from a patient undergoing cancer surgery. The method described herein is based on a hyperpolarized marker, which is contacted with the tissue sample, and an NMR spectrum and/or an MR image obtained of the tissue sample after having been contacted with the hyperpolarized marker.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 14, 2015
    Inventors: Mathilde Lerche, Magnus Karlsson, Pernille Rose Jensen
  • Publication number: 20150133441
    Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 14, 2015
    Inventor: Gerard M. Housey